HXXB Idera Pharmaceuticals Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Idera Pharmaceuticals, Inc. to BioCryst Pharmaceuticals, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Idera Pharmaceuticals, Inc. (“Idera Pharmaceuticals” or the “Company”) (NASDAQCM:IDRA) stock prior to January 22, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Idera Pharmaceuticals to BioCryst Pharmaceuticals, Inc. (NASDAQGS:BCRX). Under the terms of the transaction, Idera shareholders will receive 0.20 shares of the new company’s stock per share, while BioCryst shareholders will receive 0.50 shares of the new company’s stock per share. BioCryst shareholders will own 51.6% of the stock in the post-merger entity. To learn more about the investigation and your rights, go to:

http://www.zlk.com/mna/idera-pharmaceuticals-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Idera breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether BioCryst is underpaying for Idera shares, thus unlawfully harming Idera shareholders. An insider owning approximately 9% of Idera outstanding shares and approximately 14% of BioCryst outstanding shares has already agreed to tender his shares.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
22/01/2018

Underlying

HXXBIdera Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Idera Pharmaceuticals Inc.

 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Prov...

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today annou...

January 17, 2023 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and...

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases,” stated John Taylor, Idera’s Chief Executi...

November 14, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Acquires Aceragen

Idera Pharmaceuticals Acquires Aceragen Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there ...

September 28, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period subsequent to the August 9, 2022 filing date of the Quar...

August 9, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponso...

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC – Enrollment Stopped Early for Efficacy – EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. INTRIM 1 is a randomized, do...

May 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch